Adma Biologics (ADMA) Change in Acquisitions & Divestments (2016 - 2017)
Adma Biologics' (ADMA) quarterly Change in Acquisitions & Divestments came in at $245000.0 in Q2 2017, up 106.67% YoY from $118546.5 in Q2 2016, and down 95.24% on a QoQ basis from $5.1 million in Q1 2017.
Powered by 
Analysis
Adma Biologics (ADMA) Change in Acquisitions & Divestments (2016 - 2017) Analysis & Trends
Adma Biologics (ADMA) has 2 years of Change in Acquisitions & Divestments data on file, last reported at $245000.0 in Q2 2017.
- Quarterly Change in Acquisitions & Divestments rose 106.67% year-over-year to $245000.0 in Q2 2017, while the trailing twelve-month figure through Mar 2018 was $245000.0 (down 98.65% YoY) and the FY2017 annual result came in at $5.4 million, down 67.64% from the prior year.
- Change in Acquisitions & Divestments eased to $245000.0 in Q2 2017, from $5.1 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $16.7 million in Q4 2016 to a low of -$3.7 million in Q2 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Adma Biologics | 2.18 Bn | 2.04 Bn | 86.28 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2017 | 245,000.00 |
| Mar 31, 2017 | 5.15 Mn |
| Dec 31, 2016 | 16.66 Mn |
| Jun 30, 2016 | -3.67 Mn |
| Mar 31, 2016 | 3.67 Mn |